Know Cancer

or
forgot password

THE CLINICAL EVALUATION OF IMPLANTABLE PUMP SYSTEM FOR SAFETY AND DELIVERY ACCURACY IN PATIENTS REQUIRING INTRATHECAL ADMINISTRATION OF MORPHINE SULFATE FOR CHRONIC PAIN


Phase 2/Phase 3
21 Years
N/A
Open (Enrolling)
Both
Cancers, Chronic Pain

Thank you

Trial Information

THE CLINICAL EVALUATION OF IMPLANTABLE PUMP SYSTEM FOR SAFETY AND DELIVERY ACCURACY IN PATIENTS REQUIRING INTRATHECAL ADMINISTRATION OF MORPHINE SULFATE FOR CHRONIC PAIN


Inclusion Criteria:



1. Subject must be at least 21 years of age.

2. Subject must have experienced chronic pain for at least 6 months.

3. Subject must not presently be on intrathecal therapy but must be considered a
candidate for intrathecal analgesia by his pain specialist; or, a subject already on
intrathecal therapy must be in need of a replacement intrathecal pump and catheter.

4. Subject must be capable of giving informed consent.

5. Subjects who agree to sign a Pain Treatment Agreement (Narcotic Contract) limiting
narcotic prescriptions to the study physician.

6. Subjects who agree to periodic drug testing.

7. Subject must be capable and willing to follow all study-related procedures, including
returning for monthly refills.

8. Subject must be cognitively intact and, in the opinion of the Investigator, capable
of using the Patient Remote.

9. Subject who is not already successfully treated with intrathecal analgesic therapy
must be responsive to a trial of intrathecal or epidural morphine.

10. Female subjects of child-bearing potential must agree to use a medically acceptable
and effective double-barrier method of birth control.

11. Documented failure to respond to less invasive methods of pain control (such as
physical or behavioral modifications).

12. Ineffective pain control with single or multiple systemic analgesic treatments (oral,
rectal, IV or transdermal) or had intolerable side effects.

13. Cancer pain requiring strong opioids or non-malignant pain with average Visual Analog
Scale (VAS) score of >4/10.

14. Subjects who can receive an MRI.

15. Subjects must be able to hear and respond to audible alarms or agree to have a
support person available who is able to hear and respond to audible alarms.

Exclusion Criteria:

1. Subject is a female who is pregnant or is planning a pregnancy.

2. Subject is a nursing mother.

3. Subject has at the site chosen for implantation a skin condition that would prevent
the implantation procedure.

4. Subject has participated in an investigational drug or device trial within 4 weeks
prior to enrollment.

5. Subject has any known or suspected allergy to morphine or to the materials of the
infusion pump or intrathecal catheter.

6. Subject shows signs of active, systemic infection.

7. Subject has a known central nervous system contraindication to intrathecal therapy,
including but not limited to severe spinal canal stenosis or spinal cord compression.

8. Subject has a body size that is insufficient to accept the bulk and weight of the
pump.

9. Subject is allergic to morphine sulfate, or for whom morphine sulfate is
contraindicated.

10. Subject has a condition requiring diathermy procedures.

11. Subject has a life expectancy of less than 9 months.

12. Subject cannot independently comprehend and participate in the required assessments,
including responding to the QOL, BPI, ODI and PGIC measurement tools.

13. Subject is not considered to be medically or psychologically appropriate for pump
implantation.

14. Subject has a urine drug screen result which indicates the use of prescription drugs
or controlled substances not on the order of a physician.

15. Subjects with an ASA Physical Status >IV.

16. Subjects with a history of spinal instability, or grade II spondylolisthesis or
greater.

17. Previously implanted subjects with spinal MRI findings of inflammatory mass prior to
the implantation procedures.

18. Subjects who are unable or unwilling to return to all of the required follow-up
visits.

19. Subjects who are unwilling to sign the informed consent.

20. Subjects who are exposed to high-current industrial equipment (i.e. electricians or
electrical engineers) or regularly exposed to MRI equipment (i.e. MRI technicians,
MRI engineers and MRI clinicians).

21. Subjects with active implanted devices such as pacemakers, defibrillators, cochlear
implants and neurostimulators or other medical device use that can interfere with the
function of the implanted intrathecal pump.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

• Mean medication delivery accuracy.

Outcome Description:

Medication delivery accuracy will be evaluated at each of six (6) refills.

Outcome Time Frame:

6 months

Safety Issue:

No

Principal Investigator

Richard Rauck, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

The Center for Clinical Research

Authority:

United States: Food and Drug Administration

Study ID:

P100

NCT ID:

NCT01185470

Start Date:

February 2011

Completion Date:

December 2014

Related Keywords:

  • Cancers
  • Chronic Pain
  • Chronic pain
  • Morphine Sufate
  • Intrathecal
  • Implantable drug delivery pumps

Name

Location

The Center for Clinical ResearchWinston-Salem, North Carolina  27103
Center for Pain & Supportive CareScottsdale, Arizona  85258
University of California San DeigoLa Jolla, California  92093
NeurovationsNapa, California  94558
Millenium Pain CenterBloomington, Illinois  61701